Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA and user fees

Executive Summary

"Lower PRICED Drugs Act" is not a comprehensive measure to address all obstacles to generic drug entry, the Generic Pharmaceutical Association says. "While GPhA supports the Stabenow-Lott legislation, Pink Sheet readers should not assume, per your headline, that the bill is a 'GPhA Wish List' that will close every loophole and address all of the generic industry's concerns regarding user fees," the association states in response to the title of a 1chart in a story in "The Pink Sheet" covering the emerging debate on generic user fees (2"The Pink Sheet" Feb. 27, 2006, p. 8). "Although the Stabenow-Lott bill is a very positive measure that addresses many unintended loopholes that delay generics from coming to market, such as abuse of the citizen petition process, there are more loopholes that remain"...

You may also be interested in...



FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins

Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly

QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel